IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Immunome Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Aug 11, 2026
$16.77+0.30 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $1.90B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
118M of 114M shares
Institutional holders
202
32 new, 27 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
11 buys · 28 sales
Net sold $25.20M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 3,981,782 | 6.60% | 13G (passive) | Sep 30, 2024 |
| T. Rowe Price Investment Management, Inc. | 19,676,883 | 17.40% | 13G (passive) amendment | Jun 30, 2026 |
| Abigail P. Johnson | 13,056,709 | 15.00% | 13G (passive) amendment | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMNM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 19,676,883 | 17.32% | $416.95K | +3,312,872 | 0.27% |
| FMR LLC | 16,987,553 | 14.96% | $359.97M | +17,599 | 0.02% |
| BlackRock, Inc. | 8,805,492 | 7.75% | $186.59M | +636,818 | 0.00% |
| State Street Corp | 5,494,625 | 4.84% | $116.43M | +94,724 | 0.00% |
| Wellington Management Group Llp | 5,210,216 | 4.59% | $110.40M | +478,239 | 0.02% |
| Redmile Group, LLC | 4,911,590 | 4.32% | $104.08M | −647,295 | 6.99% |
| Primecap Management Co/Ca/ | 4,581,431 | 4.03% | $97.08M | −206,800 | 0.06% |
| Vanguard Capital Management LLC | 4,551,289 | 4.01% | $96.44M | +121,592 | 0.00% |
| Driehaus Capital Management LLC | 4,346,139 | 3.83% | $92.09M | +246,238 | 0.53% |
| Enavate Sciences Gp, LLC | 3,613,799 | 3.18% | $76.58M | – | 22.17% |
| Geode Capital Management, LLC | 2,754,889 | 2.43% | $58.39M | +194,225 | 0.00% |
| Morgan Stanley | 2,407,942 | 2.12% | $51.02M | −433,647 | 0.00% |
| Silverarc Capital Management, LLC | 2,017,009 | 1.78% | $42.74M | +166,731 | 4.44% |
| JPMorgan Chase & Co | 1,848,548 | 1.63% | $38.99M | −929,288 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 1,773,229 | 1.56% | $37.58K | −1,085,634 | 0.00% |
| Sofinnova Investments, Inc. | 1,720,316 | 1.51% | $36.45M | +18,412 | 1.88% |
| Readystate Asset Management LP | 1,605,820 | 1.41% | $34.03M | +303,958 | 1.16% |
| Goldman Sachs Group Inc | 1,512,489 | 1.33% | $32.05M | +411,013 | 0.00% |
| Vanguard Portfolio Management LLC | 1,348,979 | 1.19% | $28.58M | +342,004 | 0.00% |
| Principal Financial Group Inc | 1,347,358 | 1.19% | $28.55M | −29,509 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 202 | 118M | 100.0% | 32 / 77 | 60 / 27 | 11M | 9M |
| Q1 2026 | 202 | 117M | 100.0% | 50 / 74 | 48 / 27 | 23M | 20M |
| Q4 2025 | 183 | 120M | 100.0% | 50 / 78 | 36 / 19 | 38M | 10M |
| Q3 2025 | 153 | 91M | 80.5% | 27 / 64 | 38 / 15 | 17M | 5M |
| Q2 2025 | 142 | 79M | 69.9% | 27 / 54 | 39 / 26 | 11M | 9M |
| Q1 2025 | 142 | 77M | 67.8% | 40 / 70 | 16 / 17 | 26M | 2M |
| Q4 2024 | 120 | 53M | 46.9% | 33 / 38 | 35 / 27 | 8M | 6M |
| Q3 2024 | 115 | 52M | 45.5% | 22 / 43 | 29 / 19 | 11M | 4M |
| Q2 2024 | 114 | 48M | 42.6% | 39 / 38 | 23 / 27 | 18M | 7M |
| Q1 2024 | 103 | 38M | 33.0% | 57 / 29 | 11 / 11 | 17M | 1M |
| Q4 2023 | 57 | 22M | 19.1% | 27 / 16 | 6 / 5 | 20M | 1M |
| Q3 2023 | 35 | 3M | 2.4% | 9 / 6 | 10 / 9 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IMNM | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 7,179,563 | 6.32% | $152.13M | 1.64% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 4,740,888 | 4.17% | $103.49M | 0.10% | May 31, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 3,907,378 | 3.44% | $82.80M | 1.65% | Jun 30, 2026 |
| Vanguard Health Care Fund | 3,703,461 | 3.26% | $84.29M | 0.22% | Jul 31, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 3,692,941 | 3.25% | $84.05M | 1.14% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 3,224,392 | 2.84% | $68.32M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,991,978 | 2.63% | $63.40M | 0.59% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,745,354 | 2.42% | $58.17M | 0.07% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 2,131,664 | 1.88% | $46.53M | 0.88% | May 31, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 1,625,302 | 1.43% | $34.44M | 0.33% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 1,363,778 | 1.20% | $29.77M | 0.11% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 1,242,297 | 1.09% | $27.12M | 0.11% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 1,224,216 | 1.08% | $25.94M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,152,768 | 1.01% | $26.24M | 0.08% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,092,814 | 0.96% | $23.16M | 0.19% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Clay B. Siegall | President and CEO, Director | 870,704 | 0.77% | Jul 27, 2026 |
| Jack Higgins | Chief Scientific Officer | 81,250 | 0.07% | Sep 15, 2026 |
| Kinney Horn | CHIEF BUSINESS OFFICER | 0 | – | Aug 6, 2026 |
| Max Rosett | Chief Financial Officer | 101,287 | 0.09% | Jul 27, 2026 |
| Sandra G. Stoneman | CHIEF LEGAL OFFICER & GC | 43,805 | 0.04% | Jul 27, 2026 |
| Philip Tsai | Chief Technical Officer | 81,550 | 0.07% | Jul 27, 2026 |
| Robert Lechleider | Chief Medical Officer | 69,805 | 0.06% | Jul 27, 2026 |
| Isaac Barchas | Director | 92,211 | 0.08% | Aug 12, 2026 |
| Sandra M. Swain | Director | – | – | Jun 12, 2026 |
| Philip Wagenheim | Director | 1,168,787 | 1.03% | Jun 12, 2026 |
| Carol Schafer | Director | – | – | Jun 12, 2026 |
| James P. Boylan | Director | – | – | Jun 12, 2026 |
| Jean Jacques Bienaime | Director | 43,415 | 0.04% | Jun 12, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jack Higgins Chief Scientific Officer | Sep 11, 2026 | Option exercise | +18,000 | $1.35 | $24.30K | 78,250 |
| Jack Higgins Chief Scientific Officer | Sep 11, 2026 | Sale(10b5-1 plan) | −13,200 | $25.32 | $334.22K | 65,050 |
| Jack Higgins Chief Scientific Officer | Sep 11, 2026 | Gift | −8,800 | – | – | 56,250 |
| Isaac Barchas Director | Aug 12, 2026 | Sale(10b5-1 plan) | −11,048 | $27.25 | $301.06K | 92,211 |
| Isaac Barchas Director | Aug 11, 2026 | Sale(10b5-1 plan) | −62,291 | $26.23 | $1.63M | 0 |
| Isaac Barchas Director | Aug 10, 2026 | Sale(10b5-1 plan) | −10,125 | $26.07 | $263.96K | 62,291 |
| Isaac Barchas Director | Aug 7, 2026 | Sale(10b5-1 plan) | −15,248 | $26.06 | $397.36K | 72,416 |
| Isaac Barchas Director | Aug 6, 2026 | Sale(10b5-1 plan) | −20,840 | $26.06 | $543.09K | 87,664 |
| Kinney Horn CHIEF BUSINESS OFFICER | Aug 4, 2026 | Sale(10b5-1 plan) | −90,616 | $25.09 | $2.27M | 0 |
| Kinney Horn CHIEF BUSINESS OFFICER | Aug 4, 2026 | Option exercise | +50,366 | $12.92 | $650.73K | 50,366 |
| Kinney Horn CHIEF BUSINESS OFFICER | Aug 4, 2026 | Option exercise | +40,250 | $10.60 | $426.65K | 90,616 |
| Kinney Horn CHIEF BUSINESS OFFICER | Jul 23, 2026 | Award | +31,250 | – | – | 31,250 |
| Clay B. Siegall President and CEO, Director | Jul 23, 2026 | Award | +180,000 | – | – | 870,704 |
| Max Rosett Chief Financial Officer | Jul 23, 2026 | Award | +47,250 | – | – | 101,287 |
| Sandra G. Stoneman CHIEF LEGAL OFFICER & GC | Jul 23, 2026 | Award | +38,250 | – | – | 43,805 |
| Philip Tsai Chief Technical Officer | Jul 23, 2026 | Award | +38,250 | – | – | 81,550 |
| Jack Higgins Chief Scientific Officer | Jul 23, 2026 | Award | +38,250 | – | – | 60,250 |
| Robert Lechleider Chief Medical Officer | Jul 23, 2026 | Award | +54,000 | – | – | 69,805 |
| Kinney Horn CHIEF BUSINESS OFFICER | Jul 7, 2026 | Sale(10b5-1 plan) | −1,092 | $25.00 | $27.30K | 0 |
| Kinney Horn CHIEF BUSINESS OFFICER | Jul 7, 2026 | Option exercise | +1,092 | $12.92 | $14.11K | 1,092 |
| Isaac Barchas Director | Jul 7, 2026 | Sale(10b5-1 plan) | −16,906 | $24.20 | $409.13K | 108,504 |
| Isaac Barchas Director | Jul 6, 2026 | Sale(10b5-1 plan) | −83,094 | $24.11 | $2.00M | 125,410 |
| Robert Lechleider Chief Medical Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −22,714 | $21.95 | $498.57K | 48,091 |
| Robert Lechleider Chief Medical Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −16,214 | $22.76 | $369.03K | 31,877 |
| Robert Lechleider Chief Medical Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −16,072 | $23.44 | $376.73K | 15,805 |
| Robert Lechleider Chief Medical Officer | Jul 2, 2026 | Option exercise | +55,000 | $8.73 | $480.15K | 70,805 |
| Isaac Barchas Director | Jul 2, 2026 | Sale(10b5-1 plan) | −24,335 | $23.33 | $567.74K | 208,504 |
| Isaac Barchas Director | Jul 2, 2026 | Sale(10b5-1 plan) | −75,665 | $22.35 | $1.69M | 232,839 |
| Isaac Barchas Director | Jun 30, 2026 | Sale(10b5-1 plan) | −101,050 | $21.12 | $2.13M | 308,504 |
| Robert Lechleider Chief Medical Officer | Jun 25, 2026 | Sale(10b5-1 plan) | −14,420 | $20.66 | $297.92K | 15,805 |
| Robert Lechleider Chief Medical Officer | Jun 25, 2026 | Option exercise | +55,000 | $8.73 | $480.15K | 70,805 |
| Robert Lechleider Chief Medical Officer | Jun 25, 2026 | Sale(10b5-1 plan) | −40,580 | $19.56 | $793.74K | 30,225 |
| Max Rosett Chief Financial Officer | Jun 15, 2026 | Option exercise | +60,000 | $1.05 | $63.00K | 114,037 |
| Max Rosett Chief Financial Officer | Jun 15, 2026 | Sale(10b5-1 plan) | −60,000 | $18.23 | $1.09M | 54,037 |
| Jean Jacques Bienaime Director | Jun 5, 2026 | Buy | +1,000 | $19.27 | $19.27K | 43,415 |
| Jean Jacques Bienaime Director | Jun 5, 2026 | Buy | +3,500 | $19.46 | $68.11K | 42,415 |
| Jean Jacques Bienaime Director | Jun 5, 2026 | Buy | +6,000 | $19.48 | $116.88K | 38,915 |
| Jean Jacques Bienaime Director | Jun 5, 2026 | Sale | −10,000 | $19.41 | $194.10K | 32,915 |
| Jean Jacques Bienaime Director | Jun 5, 2026 | Sale | −500 | $19.44 | $9.72K | 42,915 |
| Jean Jacques Bienaime Director | May 15, 2026 | Buy | +5,000 | $20.70 | $103.50K | 43,415 |
| Max Rosett Chief Financial Officer | Apr 2, 2026 | Option exercise | +31,848 | $1.05 | $33.44K | 79,324 |
| Max Rosett Chief Financial Officer | Apr 2, 2026 | Option exercise | +39,713 | $1.35 | $53.61K | 119,037 |
| Max Rosett Chief Financial Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −63,656 | $21.91 | $1.39M | 55,381 |
| Max Rosett Chief Financial Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −1,344 | $22.48 | $30.21K | 54,037 |
| Jack Higgins Chief Scientific Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −9,438 | $21.64 | $204.24K | 22,000 |
| Jack Higgins Chief Scientific Officer | Mar 30, 2026 | Gift | −6,291 | – | – | 31,438 |
| Clay B. Siegall President and CEO, Director | Mar 27, 2026 | Buy | +25,450 | $19.67 | $500.60K | 690,704 |
| Philip Wagenheim Director | Mar 23, 2026 | Sale | −28,200 | $20.65 | $582.33K | 341,147 |
| Philip Wagenheim Director | Mar 20, 2026 | Sale | −36,800 | $20.47 | $753.30K | 369,347 |
| Jean Jacques Bienaime Director | Mar 11, 2026 | Buy | +1,000 | $21.55 | $21.55K | 38,415 |
| Jean Jacques Bienaime Director | Mar 10, 2026 | Buy | +1,000 | $22.12 | $22.12K | 37,415 |
| Clay B. Siegall President and CEO, Director | Dec 30, 2025 | Buy | +4,729 | $21.15 | $100.02K | 665,254 |
| Isaac Barchas Director | Dec 22, 2025 | Sale(10b5-1 plan) | −11,251 | $22.34 | $251.35K | 2,031,181 |
| Isaac Barchas Director | Dec 22, 2025 | Sale(10b5-1 plan) | −371,949 | $21.72 | $8.08M | 2,042,432 |
| Jack Higgins Chief Scientific Officer | Dec 19, 2025 | Gift | +1,000 | – | – | 1,000 |
| Jack Higgins Chief Scientific Officer | Dec 19, 2025 | Gift | −1,000 | – | – | 38,729 |
| Jack Higgins Chief Scientific Officer | Dec 19, 2025 | Gift | −1,000 | – | – | 39,729 |
| Jack Higgins Chief Scientific Officer | Dec 19, 2025 | Gift | −1,000 | – | – | 37,729 |
| Jack Higgins Chief Scientific Officer | Dec 19, 2025 | Gift | +1,000 | – | – | 1,000 |
| Jack Higgins Chief Scientific Officer | Dec 19, 2025 | Gift | +1,000 | – | – | 1,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jack Higgins Officer | Sep 11, 2026 | 13,200 | $334.22K | Sep 11, 2026 | Stock Option Exercise |
| Isaac Barchas Director | Aug 12, 2026 | 11,048 | $301.06K | Aug 12, 2026 | Investment Distribution |
| Abhmc Ii, Llc Shareholder | Aug 6, 2026 | 108,504 | $2.77M | Aug 6, 2026 | Private Placement |
| Kinney Horn Officer | Aug 4, 2026 | 90,616 | $2.27M | Aug 4, 2026 | Stock Option Exercise |
| Kinney Horn Officer | Jul 7, 2026 | 1,092 | $27.30K | Jul 7, 2026 | Stock Option Exercise |
| Abhmc Ii, Llc Shareholder | Jul 6, 2026 | 100,000 | $2.36M | Jul 6, 2026 | Private Placement |
| Abhmc Ii, Llc Shareholder | Jul 2, 2026 | 100,000 | $2.15M | Jul 2, 2026 | Private Placement |
| Robert Lechleider Officer | Jul 2, 2026 | 55,000 | $1.19M | Jul 2, 2026 | Stock Option Exercise |
| Arsenal Bridge Venture II-B, LLC Shareholder | Jun 30, 2026 | 1,050 | $22.09K | Jun 30, 2026 | Private Placement |
| Abhmc Ii, Llc Shareholder | Jun 30, 2026 | 100,000 | $2.10M | Jun 30, 2026 | Private Placement |
| Robert Lechleider Officer | Jun 25, 2026 | 55,000 | $1.09M | Jun 25, 2026 | Stock Option Exercise |
| Max Rosett Officer | Jun 15, 2026 | 60,000 | $1.12M | Jun 15, 2026 | Stock Option Exercise |
| Max Rosett Officer | Apr 3, 2026 | 65,000 | $1.43M | Apr 2, 2026 | Stock Option Exercise |
| Jack Higgins Officer | Apr 2, 2026 | 9,438 | $204.24K | Apr 2, 2026 | Stock Option Exercise |
| Max Rosett Officer | Apr 2, 2026 | 65,000 | $4.72M | Apr 2, 2026 | Stock Option Exercise |